Complement Dependent Cytotoxicity (cdc) - Cancer Science

Relevant Publications

Tumor-Suppressive Cross-Linking of Anti- Antibodies in Acute Lymphoblastic Leukemia.

Issue Release: 2024

Anti-HER2 Cancer-Specific mAb, HMab-250-hG, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab.

Issue Release: 2024

Successful Desensitization with Imlifidase and Daratumumab in a Highly Immunized, Crossmatch Positive, Blood Group-Incompatible Living-Donor Re-Transplant Recipient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome.

Issue Release: 2024

Label-free assessment of complement-dependent cytotoxicity of therapeutic antibodies via a whole-cell MALDI mass spectrometry bioassay.

Issue Release: 2024

Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.

Issue Release: 2024

A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer.

Issue Release: 2024

Chemoenzymatic synthesis and immunological evaluation of sialyl-Thomsen-Friedenreich (sTF) antigen conjugate to CRM197.

Issue Release: 2024

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.

Issue Release: 2024

Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms.

Issue Release: 2024

Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation.

Issue Release: 2024

Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis.

Issue Release: 2024

In Situ Self-Assembly of Antibody-Rhamnose Complex as a Pre-Targeting Strategy for Enhanced Cancer Immunotherapy.

Issue Release: 2024

Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro.

Issue Release: 2024

SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity.

Issue Release: 2024

Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3.

Issue Release: 2024

Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.

Issue Release: 2024

Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.

Issue Release: 2024

Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients.

Issue Release: 2024

Introduction of the donor centre virtual crossmatch in Eurotransplant.

Issue Release: 2024

Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement.

Issue Release: 2024

What Role Do Bayesian Models Play in Clinical Trials?

What is a Thyroidectomy?

How Do Personalized Medicine and Drug Formulations Intersect?

How Can Bitbucket Enhance Collaboration in Cancer Research?

How are Ronald McDonald Houses funded?

What Are the Limitations of Mammography?

How Can Families Support Patients?

How to Handle Hair Loss?

How to Prepare for a Genetic Counseling Appointment?

What are the Benefits and Risks of IM Administration?

Complement Dependent Cytotoxicity (cdc) - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics